Tag Archive for: licensing agreement

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor

/in

August 20th, 2024, Copenhagen, Denmark and Shanghai, China — Adcendo ApS (“Adcendo”) and Multitude Therapeutics Inc. (“Multitude”) jointly announced today that they have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02. Under this agreement, Adcendo will obtain the exclusive development and commercialization […]

Read more

Delsitech announces a major licensing agreement on drug delivery

/in

Turku, Finland – 23rd May, 2024. Clinical-stage drug delivery and development company, DelSiTech Ltd, today announced that the company has entered into a Licensing Agreement with an undisclosed global pharmaceutical company. According to the Licensing Agreement, DelSiTech grants an exclusive global license to DelSiTech’s Silica Matrix based, controlled release technology for development and commercialization of […]

Read more

SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline

/in

Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies  SOTIO to develop up to three next generation bioconjugates  Total potential deal value of up to $740 million, plus royalties on commercial sales for three ADC programs  AMSTERDAM, THE NETHERLANDS, 16 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage […]

Read more

ABL Bio Taps into Synaffix ADC Technology

/in

License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation bioconjugates AMSTERDAM, THE NETHERLANDS, 13 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibodydrug conjugates (ADCs) with […]

Read more

Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza

/in

Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray Toxicology studies support safety profile Manufacturing process established Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam Phase 1 clinical studies completed successfully in Vietnam by HURO Retail product based on SPOR COV technology […]

Read more